Resistance to cancer immunotherapy in metastatic renal cell carcinoma.
Tumor microenvironment
clear cell renal cell carcinoma
immune checkpoint inhibitor
immune checkpoint inhibitor resistance
Journal
Cancer drug resistance (Alhambra, Calif.)
ISSN: 2578-532X
Titre abrégé: Cancer Drug Resist
Pays: United States
ID NLM: 101738710
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
03
2020
revised:
06
05
2020
accepted:
29
05
2020
entrez:
18
5
2022
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
The prognosis of metastatic clear cell renal cell carcinoma (mccRCC) has changed dramatically over the years with the emergence of immune checkpoint inhibitors (ICI) used alone, or in combination with another ICI, or with vascular endothelial growth factor receptor tyrosine kinase inhibitor. Although major response rates have been observed with ICI, many patients do not respond, reflecting primary resistance, and durable responses remain exceptional, reflecting secondary resistance. Factors contributing to primary and acquired resistance are manifold, including patient-intrinsic factors, tumor cell-intrinsic factors and factors associated with the tumoral microenvironment (TME). While some mechanisms of resistance are common to several tumor types, others are specific to mccRCC. Predictive biomarkers and alternative strategies are needed to overcome this resistance. This review provides an overview of the major ICI resistance mechanisms, highlights the potential of the TME to induce resistance to ICI, and discusses the predictive biomarkers available to guide therapeutic choice.
Identifiants
pubmed: 35582435
doi: 10.20517/cdr.2020.16
pmc: PMC8992500
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
454-471Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Not applicable.
Références
Nature. 2014 Nov 27;515(7528):577-81
pubmed: 25428507
Cancers (Basel). 2014 Aug 13;6(3):1670-90
pubmed: 25125485
Front Immunol. 2016 Feb 16;7:52
pubmed: 26909082
Curr Opin Clin Nutr Metab Care. 2018 May;21(3):145-151
pubmed: 29369114
Cancer Discov. 2018 Feb;8(2):216-233
pubmed: 29101163
Science. 2018 Feb 16;359(6377):770-775
pubmed: 29301958
Cell Rep. 2015 May 19;11(7):1018-30
pubmed: 25959818
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Nat Commun. 2017 Oct 26;8(1):1136
pubmed: 29070816
Nat Rev Immunol. 2020 Jan;20(1):25-39
pubmed: 31570880
J Clin Oncol. 2015 Oct 1;33(28):3193-8
pubmed: 26282644
Nat Rev Clin Oncol. 2018 May;15(5):310-324
pubmed: 29434333
Cancer Sci. 2019 May;110(5):1564-1572
pubmed: 30861269
Clin Cancer Res. 2009 Oct 1;15(19):6225-31
pubmed: 19755389
Nat Rev Clin Oncol. 2018 Jun;15(6):382-396
pubmed: 29636538
Ann Oncol. 2018 Jun 1;29(6):1437-1444
pubmed: 29617710
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Cancer Res. 2017 Mar 1;77(5):1075-1082
pubmed: 27872087
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Cancer Sci. 2011 Jul;102(7):1424-31
pubmed: 21453387
Cancer Sci. 2018 May;109(5):1583-1591
pubmed: 29498788
Cell Mol Immunol. 2017 Aug;14(8):662-674
pubmed: 28626234
Cell. 2018 Nov 1;175(4):984-997.e24
pubmed: 30388455
Clin Cancer Res. 2015 Jul 1;21(13):3031-40
pubmed: 25688160
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Curr Opin Oncol. 2019 May;31(3):194-199
pubmed: 30985497
J Immunother Cancer. 2017 Jul 18;5(1):53
pubmed: 28716061
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
Mol Med Today. 2000 Jan;6(1):15-9
pubmed: 10637570
Eur J Cancer. 2013 Apr;49(6):1287-96
pubmed: 23321547
J Transl Med. 2018 Mar 20;16(1):75
pubmed: 29558948
Diagn Pathol. 2018 Aug 25;13(1):60
pubmed: 30144808
Cell. 2017 Aug 24;170(5):927-938.e20
pubmed: 28841418
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
Clin Cancer Res. 2019 Apr 1;25(7):2174-2184
pubmed: 30670497
Immunity. 2015 Apr 21;42(4):607-12
pubmed: 25902480
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Cell Rep. 2018 Apr 3;23(1):313-326.e5
pubmed: 29617669
Lancet Oncol. 2019 Aug;20(8):1083-1097
pubmed: 31221619
Front Immunol. 2018 Jan 29;9:40
pubmed: 29434587
Nat Med. 2019 Nov;25(11):1715-1720
pubmed: 31700181
Cell Rep. 2014 May 22;7(4):1130-42
pubmed: 24813893
Cancer Res. 2010 Jul 1;70(13):5213-9
pubmed: 20551059
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
Hematol Oncol Clin North Am. 2011 Aug;25(4):793-812
pubmed: 21763968
Cancer Immunol Immunother. 2013 Dec;62(12):1757-68
pubmed: 24132754
Lancet Oncol. 2017 Aug;18(8):1009-1021
pubmed: 28694034
Clin Cancer Res. 2015 Mar 15;21(6):1329-39
pubmed: 25583177
J Cell Physiol. 2003 Jun;195(3):346-55
pubmed: 12704644
FEBS J. 2019 Nov;286(21):4160-4175
pubmed: 31365790
Lancet Oncol. 2018 Jun;19(6):737-746
pubmed: 29778737
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Nature. 2017 Aug 24;548(7668):471-475
pubmed: 28813415
Nat Immunol. 2015 Dec;16(12):1235-44
pubmed: 26502405
Nat Rev Immunol. 2005 May;5(5):375-86
pubmed: 15864272
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
Genes Cancer. 2018 May;9(5-6):176-189
pubmed: 30603054
Cancer Drug Resist. 2019;2:141-160
pubmed: 34322663
Onco Targets Ther. 2018 Oct 16;11:7005-7009
pubmed: 30410357
ESMO Open. 2019 Feb 27;4(1):e000457
pubmed: 30964126
J Neurosci Res. 2006 Aug 1;84(2):370-8
pubmed: 16676326
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Clin Cancer Res. 2017 Aug 1;23(15):4416-4428
pubmed: 28213366
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Clin Cancer Res. 2015 Feb 1;21(3):632-41
pubmed: 25056374
Front Oncol. 2019 Jun 14;9:490
pubmed: 31259150
Cancer Immunol Res. 2016 Jul;4(7):563-8
pubmed: 27197067
BMJ. 2018 Sep 10;362:k3529
pubmed: 30201790
J Exp Med. 1993 Feb 1;177(2):265-72
pubmed: 8426105
Lancet Oncol. 2016 Jul;17(7):917-927
pubmed: 27279544
Nat Med. 2008 Nov;14(11):1256-63
pubmed: 18978796
J Clin Oncol. 2018 Nov 10;36(32):3223-3230
pubmed: 30265610
Immunity. 2018 Jan 16;48(1):147-160.e7
pubmed: 29343435
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
Oncologist. 2020 Jan;25(1):55-63
pubmed: 31292268
Sci Rep. 2020 Jan 29;10(1):1456
pubmed: 31996766
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
JAMA Oncol. 2019 Nov 1;5(11):1631-1633
pubmed: 31486842
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
Curr Opin Immunol. 2007 Apr;19(2):203-8
pubmed: 17292599
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Ann Oncol. 2014 Jul;25(7):1293-1311
pubmed: 24644304
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Science. 2018 Feb 2;359(6375):582-587
pubmed: 29217585
Kidney Cancer. 2017 Jul 26;1(1):3-13
pubmed: 30334000
Ann Oncol. 2019 Oct 1;30(10):1572-1579
pubmed: 31268133
Int Immunol. 2007 Mar;19(3):337-43
pubmed: 17267414
J Clin Oncol. 2009 Aug 1;27(22):3584-90
pubmed: 19487381
Nature. 2011 Jan 27;469(7331):539-42
pubmed: 21248752